Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
The state-of-the-art facility is expected to be commissioned over the next three years
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Subscribe To Our Newsletter & Stay Updated
